论文部分内容阅读
[目的]探讨CD44V6、C-erbB-2、EGFR在卵巢上皮性癌中的表达及意义。[方法]应用免疫组化S-P法检测卵巢上皮性癌42例,卵巢良性肿瘤22例及10例正常卵巢组织中CD44V6、C-erbB-2和EGFR表达。[结果]CD44V6、C-erbB-2、EGFR在卵巢上皮性癌中的阳性表达率分别为38.10%、57.14%、76.19%,显著高于正常组织(10%、10%、0)和卵巢良性肿瘤(4.55%、9.09%、13.64%)。[结论]CD44V6、C-erbB-2、EGFR分子与卵巢上皮性癌的发生、发展有关。
[Objective] To investigate the expression and significance of CD44V6, C-erbB-2 and EGFR in epithelial ovarian cancer. [Method] The expressions of CD44V6, C-erbB-2 and EGFR in 42 cases of ovarian epithelial carcinoma, 22 cases of benign ovarian tumor and 10 cases of normal ovarian tissue were detected by immunohistochemical S-P method. [Results] The positive rates of CD44V6, C-erbB-2 and EGFR in epithelial ovarian cancer were 38.10%, 57.14% and 76.19%, respectively, which were significantly higher than those in normal tissues (10%, 10%, 0) Tumors (4.55%, 9.09%, 13.64%). [Conclusion] The expressions of CD44V6, C-erbB-2 and EGFR are associated with the occurrence and development of epithelial ovarian cancer.